First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is a publicly traded the market company. As of May 21, 2026, TRAX trades at $16.02 with a market cap of $620.74M and a P/E ratio of 0.00. TRAX moved -2.16% today. Year to date, TRAX is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $14.79 to $25.58. Analyst consensus is strong buy with an average price target of $38.50. Rallies surfaces TRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
First Tracks Biotherapeutics Debuts on Nasdaq with $180M Cash and Two-Year Runway: First Tracks Biotherapeutics launched as an independent clinical-stage company on Nasdaq under TRAX with $180 million in cash and a two-year runway. Its pipeline includes three antibody programs: ANB033 in Phase 1b for celiac disease and eosinophilic esophagitis, rosnilimab in a Phase 2b rheumatoid arthritis trial and ANB101 in Phase 1a.
| Metric | Value |
|---|---|
| Price | $16.02 |
| Market Cap | $620.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.58 |
| 52-Week Low | $14.79 |
| Volume | 78 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover TRAX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.50.